Literature DB >> 16914407

CNS manifestations of Fabry's disease.

Andreas Fellgiebel1, Matthias J Müller, Lionel Ginsberg.   

Abstract

BACKGROUND: Fabry's disease is a rare hereditary lysosomal storage disease with multiorgan involvement. Deficiency of alpha-galactosidase A activity leads to accumulation of neutral glycosphingolipids, especially in vascular endothelial and smooth-muscle cells. Along with progressive renal and cardiac dysfunction, stroke is a major and often life-threatening burden of the disease. Cerebral vasculopathy, confirmed by neuropathological, neuroradiological, and functional studies, occurs commonly and leads to ischaemic cerebrovascular events at an early age. RECENT DEVELOPMENTS: Fabry's disease is an X-linked disease and women have been regarded as only mildly affected carriers. However, research has shown a high prevalence of ischaemic stroke and transient ischaemic attacks, along with imaging evidence of CNS involvement, in female patients with the disease, which suggests that at least in a subgroup of clinically affected women the severity of CNS disease is comparable to that in men. Another study has shown a high prevalence of the disease in young patients of both sexes with cryptogenic stroke, emphasising the need for more clinical attention to be paid to this under-diagnosed disease. WHERE NEXT?: These new findings should be replicated in larger samples. Brain structural changes and CNS involvement in the disease need to be monitored carefully in follow-up studies to broaden our knowledge of the course of neurobiological changes and to identify potential effects of enzyme-replacement therapy, which is already showing some benefit in cardiac and renal dysfunction in the disease. Finally, a diagnosis of Fabry's disease should always be considered in young patients who have had a stroke.

Entities:  

Mesh:

Year:  2006        PMID: 16914407     DOI: 10.1016/S1474-4422(06)70548-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  48 in total

1.  Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease.

Authors:  Andreas Fellgiebel; Dominik O Wolf; Edwin Kolodny; Matthias J Müller
Journal:  J Inherit Metab Dis       Date:  2011-09-20       Impact factor: 4.982

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

4.  [Ocular motility disorders in a patient with Fabry's disease].

Authors:  B Fiore; M Klopfer; C Schwebig; A Wiescher; I Lanzl
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

Review 5.  Genetic susceptibility to ischemic stroke.

Authors:  James F Meschia; Bradford B Worrall; Stephen S Rich
Journal:  Nat Rev Neurol       Date:  2011-05-31       Impact factor: 42.937

6.  Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?

Authors:  Carla Pinto Moura; Carlos Soares; Daniela Seixas; Margarida Ayres-Bastos; João Paulo Oliveira
Journal:  JIMD Rep       Date:  2012-03-24

7.  Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia.

Authors:  Laura Fancellu; Walter Borsini; Ilaria Romani; Angelo Pirisi; Giovanni Andrea Deiana; Elia Sechi; Pietro Emiliano Doneddu; Anna Laura Rassu; Rita Demurtas; Anna Scarabotto; Pamela Cassini; Eloisa Arbustini; GianPietro Sechi
Journal:  BMC Neurol       Date:  2015-12-12       Impact factor: 2.474

8.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

9.  Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.

Authors:  Alessandro Salviati; Alessandro P Burlina; Walter Borsini
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

10.  Excessive Daytime Sleepiness Is a Common Symptom in Fabry Disease.

Authors:  Thomas Duning; Michael Deppe; Simon Keller; Hagen Schiffbauer; Jörg Stypmann; Matthias Böntert; Roland Schaefer; Peter Young
Journal:  Case Rep Neurol       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.